The main therapeutic approaches targeting HK2 include reducing its catalytic activity by inhibiting its expression, directly inhibiting its enzymatic activity to block glucose phosphorylation, and disrupting its interaction with mitochondria to cut off an important energy pathway for tumor cells. The gene discussed is HK2; the disease is neoplasm.